Literature DB >> 33210321

A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models.

Michael J Martens1, Brent R Logan1.   

Abstract

To ensure that a study can properly address its research aims, the sample size and power must be determined appropriately. Covariate adjustment via regression modeling permits more precise estimation of the effect of a primary variable of interest at the expense of increased complexity in sample size/power calculation. The presence of correlation between the main variable and other covariates, commonly seen in observational studies and non-randomized clinical trials, further complicates this process. Though sample size and power specification methods have been obtained to accommodate specific covariate distributions and models, most existing approaches rely on either simple approximations lacking theoretical support or complex procedures that are difficult to apply at the design stage. The current literature lacks a general, coherent theory applicable to a broader class of regression models and covariate distributions. We introduce succinct formulas for sample size and power determination with the generalized linear, Cox, and Fine-Gray models that account for correlation between a main effect and other covariates. Extensive simulations demonstrate that this method produces studies that are appropriately sized to meet their type I error rate and power specifications, particularly offering accurate sample size/power estimation in the presence of correlated covariates.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  biomarkers; generalized linear models; sample size/power determination; study design; time to event regression; variance inflation factor

Mesh:

Year:  2020        PMID: 33210321      PMCID: PMC8020892          DOI: 10.1002/sim.8823

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Sample size considerations for the evaluation of prognostic factors in survival analysis.

Authors:  C Schmoor; W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

2.  Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates.

Authors:  F Y Hsieh; P W Lavori
Journal:  Control Clin Trials       Date:  2000-12

3.  Power and sample size calculations for generalized regression models with covariate measurement error.

Authors:  Tor D Tosteson; Jeffrey S Buzas; Eugene Demidenko; Margaret Karagas
Journal:  Stat Med       Date:  2003-04-15       Impact factor: 2.373

4.  Sample size formula for proportional hazards modelling of competing risks.

Authors:  Aurélien Latouche; Raphaël Porcher; Sylvie Chevret
Journal:  Stat Med       Date:  2004-11-15       Impact factor: 2.373

5.  A simple method of sample size calculation for linear and logistic regression.

Authors:  F Y Hsieh; D A Bloch; M D Larsen
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

6.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

7.  A group sequential test for treatment effect based on the Fine-Gray model.

Authors:  Michael J Martens; Brent R Logan
Journal:  Biometrics       Date:  2018-03-13       Impact factor: 2.571

8.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Authors:  Mohammad Abu Zaid; Juan Wu; Cindy Wu; Brent R Logan; Jeffrey Yu; Corey Cutler; Joseph H Antin; Sophie Paczesny; Sung Won Choi
Journal:  Blood       Date:  2016-11-08       Impact factor: 22.113

9.  Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.

Authors:  Peter B Gilbert; Holly E Janes; Yunda Huang
Journal:  Stat Med       Date:  2016-03-31       Impact factor: 2.373

10.  Dichotomizing continuous predictors in multiple regression: a bad idea.

Authors:  Patrick Royston; Douglas G Altman; Willi Sauerbrei
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.